Thiolysable prodrugs of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine with antineoplastic activity
摘要:
Several 2-alkoxycarbonyl- and 2-aryloxycarbonyl-1,2-bis(methylsulfony1)-1- (2-chloroethyl)hydrazines, conceived as thiolysable prodrugs of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, were synthesized and their antineoplastic activity evaluated against the L1210 leukemia in mice. In addition to producing 'cures' of mice bearing this tumor, many of the analogues were preferentially activated by glutathione (GSH) and/or glutathione S-transferase (GST), making them potentially useful in the treatment of multidrug resistant tumors with increased intracellular levels of GSH and/or GST. (C) Elsevier, Paris.
N,N'-BIS(SULFONYL)HYDRAZINES USEFUL AS ANTINEOPLASTIC AGENTS
申请人:Yale University
公开号:EP1028721B1
公开(公告)日:2003-06-04
US6040338A
申请人:——
公开号:US6040338A
公开(公告)日:2000-03-21
Thiolysable prodrugs of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine with antineoplastic activity
作者:Krishnamurthy Shyam、Philip G. Penketh、Regina H. Loomis、Alan C. Sartorelli
DOI:10.1016/s0223-5234(98)80019-6
日期:1998.7
Several 2-alkoxycarbonyl- and 2-aryloxycarbonyl-1,2-bis(methylsulfony1)-1- (2-chloroethyl)hydrazines, conceived as thiolysable prodrugs of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, were synthesized and their antineoplastic activity evaluated against the L1210 leukemia in mice. In addition to producing 'cures' of mice bearing this tumor, many of the analogues were preferentially activated by glutathione (GSH) and/or glutathione S-transferase (GST), making them potentially useful in the treatment of multidrug resistant tumors with increased intracellular levels of GSH and/or GST. (C) Elsevier, Paris.
N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents
申请人:Yale University
公开号:US06040338A1
公开(公告)日:2000-03-21
The present invention relates to a compound of the formula wherein R.sup.1 and R.sup.2 are selected from lower alkyl groups having 1-6 carbon atoms, substituted or unsubstituted aryl groups, and unsaturated alkyl groups having 1-6 carbon atoms; R.sup.3 is a substituted or unsubstituted lower alkyl group having 1-6 carbons; and R.sup.4 is selected from substituted or unsubstituted lower alkyl groups having 1-6 carbon atoms, substituted or unsubstituted aryl groups, and unsaturated alkyl groups having 1-6 carbon atoms. The present invention also relates to a pharmaceutical composition comprising the above compound, as well as a method of treating tumor cells with the compound.